About the Company

Adocia (NYSE Euronext: ADOC.PA) is a biopharmaceutical company focused on designing next generation, best-in-class insulin formulations using its proprietary BioChaperone technology. Adocia’s objective is to out-license its products after establishing proof-of-concept in clinical trials. This strategy has been validated with a recently signed licensing agreement with Eli Lilly worth up to $570 million for the ultra-fast acting BioChaperone Lispro program. Adocia is also developing a product containing both fast-acting and long-acting insulins called BioChaperone Combo, a BioChaperone recombinant human insulin formulation, and a wounding healing product, BioChaperone PDGF-BB.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research